vs
INTERGROUP CORP（INTG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是INTERGROUP CORP的1.8倍（$30.3M vs $17.3M），INTERGROUP CORP净利率更高（8.8% vs -221.3%，领先230.1%），REGENXBIO Inc.同比增速更快（43.0% vs 19.8%），INTERGROUP CORP自由现金流更多（$-481.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.8%）
Intergroup Corp是一家多元化控股企业，核心业务覆盖房地产与酒店运营两大板块。公司在美国境内持有、管理及租赁商住类物业，同时运营面向休闲和商务旅客的有限服务型酒店。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
INTG vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$17.3M
营收增速更快
RGNX
高出23.2%
19.8%
净利率更高
INTG
高出230.1%
-221.3%
自由现金流更多
INTG
多$52.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.3M | $30.3M |
| 净利润 | $1.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 11.6% | -190.0% |
| 净利率 | 8.8% | -221.3% |
| 营收同比 | 19.8% | 43.0% |
| 净利润同比 | 155.6% | -31.2% |
| 每股收益（稀释后） | $0.71 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INTGRGNX
| Q4 25 | $17.3M | $30.3M | ||
| Q3 25 | $17.9M | $29.7M | ||
| Q2 25 | $16.2M | $21.4M | ||
| Q1 25 | $16.8M | $89.0M | ||
| Q4 24 | $14.4M | $21.2M | ||
| Q3 24 | $16.9M | $24.2M | ||
| Q2 24 | $13.4M | $22.3M | ||
| Q1 24 | $14.9M | $15.6M |
净利润INTGRGNX
| Q4 25 | $1.5M | $-67.1M | ||
| Q3 25 | $-535.0K | $-61.9M | ||
| Q2 25 | $-2.2M | $-70.9M | ||
| Q1 25 | $-578.0K | $6.1M | ||
| Q4 24 | $-2.7M | $-51.2M | ||
| Q3 24 | $-398.0K | $-59.6M | ||
| Q2 24 | $-4.9M | $-53.0M | ||
| Q1 24 | $-3.2M | $-63.3M |
毛利率INTGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率INTGRGNX
| Q4 25 | 11.6% | -190.0% | ||
| Q3 25 | 15.3% | -176.3% | ||
| Q2 25 | 8.1% | -296.3% | ||
| Q1 25 | 14.0% | 13.6% | ||
| Q4 24 | 5.9% | -242.1% | ||
| Q3 24 | 18.5% | -256.6% | ||
| Q2 24 | 3.7% | -251.3% | ||
| Q1 24 | 4.8% | -408.8% |
净利率INTGRGNX
| Q4 25 | 8.8% | -221.3% | ||
| Q3 25 | -3.0% | -208.3% | ||
| Q2 25 | -13.9% | -331.8% | ||
| Q1 25 | -3.4% | 6.8% | ||
| Q4 24 | -18.9% | -241.3% | ||
| Q3 24 | -2.4% | -246.3% | ||
| Q2 24 | -36.7% | -237.7% | ||
| Q1 24 | -21.3% | -405.4% |
每股收益（稀释后）INTGRGNX
| Q4 25 | $0.71 | $-1.30 | ||
| Q3 25 | $-0.25 | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | $-0.27 | $0.12 | ||
| Q4 24 | $-1.26 | $-0.99 | ||
| Q3 24 | $-0.18 | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | $-1.44 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.5M | $230.1M |
| 总债务越低越好 | $233.2M | — |
| 股东权益账面价值 | $-85.2M | $102.7M |
| 总资产 | $101.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INTGRGNX
| Q4 25 | $7.5M | $230.1M | ||
| Q3 25 | $6.0M | $274.2M | ||
| Q2 25 | $6.1M | $323.3M | ||
| Q1 25 | $4.8M | $267.9M | ||
| Q4 24 | $15.4M | $234.7M | ||
| Q3 24 | $12.2M | $255.5M | ||
| Q2 24 | $11.6M | $290.4M | ||
| Q1 24 | $19.5M | $338.7M |
总债务INTGRGNX
| Q4 25 | $233.2M | — | ||
| Q3 25 | $237.8M | — | ||
| Q2 25 | $240.5M | — | ||
| Q1 25 | $241.5M | — | ||
| Q4 24 | $227.2M | — | ||
| Q3 24 | $218.1M | — | ||
| Q2 24 | $225.7M | — | ||
| Q1 24 | $225.0M | — |
股东权益INTGRGNX
| Q4 25 | $-85.2M | $102.7M | ||
| Q3 25 | $-86.7M | $161.5M | ||
| Q2 25 | $-86.1M | $213.7M | ||
| Q1 25 | $-84.5M | $274.2M | ||
| Q4 24 | $-83.9M | $259.7M | ||
| Q3 24 | $-80.9M | $301.4M | ||
| Q2 24 | $-80.3M | $348.3M | ||
| Q1 24 | $-76.4M | $390.7M |
总资产INTGRGNX
| Q4 25 | $101.1M | $453.0M | ||
| Q3 25 | $102.5M | $525.2M | ||
| Q2 25 | $104.1M | $581.0M | ||
| Q1 25 | $103.2M | $490.9M | ||
| Q4 24 | $110.6M | $466.0M | ||
| Q3 24 | $109.3M | $519.1M | ||
| Q2 24 | $107.8M | $569.4M | ||
| Q1 24 | $119.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-23.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-481.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -2.8% | -174.0% |
| 资本支出强度资本支出/营收 | 2.6% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.02× | — |
| 过去12个月自由现金流最近4个季度 | $739.0K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流INTGRGNX
| Q4 25 | $-23.0K | $-52.3M | ||
| Q3 25 | $-296.0K | $-56.0M | ||
| Q2 25 | $5.9M | $-49.3M | ||
| Q1 25 | $-854.0K | $33.6M | ||
| Q4 24 | $-781.0K | $-31.6M | ||
| Q3 24 | $3.4M | $-40.5M | ||
| Q2 24 | $6.8M | $-45.5M | ||
| Q1 24 | $1.9M | $-55.5M |
自由现金流INTGRGNX
| Q4 25 | $-481.0K | $-52.8M | ||
| Q3 25 | $-1.3M | $-56.5M | ||
| Q2 25 | $3.6M | $-49.7M | ||
| Q1 25 | $-1.2M | $32.6M | ||
| Q4 24 | $-1.1M | $-32.7M | ||
| Q3 24 | $3.1M | $-40.9M | ||
| Q2 24 | $2.7M | $-46.0M | ||
| Q1 24 | $1.1M | $-56.0M |
自由现金流率INTGRGNX
| Q4 25 | -2.8% | -174.0% | ||
| Q3 25 | -7.1% | -189.9% | ||
| Q2 25 | 22.5% | -232.8% | ||
| Q1 25 | -6.8% | 36.6% | ||
| Q4 24 | -7.8% | -154.2% | ||
| Q3 24 | 18.3% | -168.9% | ||
| Q2 24 | 20.4% | -206.2% | ||
| Q1 24 | 7.6% | -358.5% |
资本支出强度INTGRGNX
| Q4 25 | 2.6% | 1.7% | ||
| Q3 25 | 5.4% | 1.7% | ||
| Q2 25 | 13.9% | 1.8% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 2.4% | 5.1% | ||
| Q3 24 | 1.6% | 1.3% | ||
| Q2 24 | 30.4% | 2.1% | ||
| Q1 24 | 4.9% | 3.6% |
现金转化率INTGRGNX
| Q4 25 | -0.02× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
